Prospects of anti-B-cell therapy for systemic sclerosis
https://doi.org/10.47360/1995-4484-2025-219-228
Abstract
Systemic sclerosis (SSc) is a severe systemic autoimmune rheumatic disease (SARD), pathogenetically associated with inflammation and pathological disorders in the microvascular bed, leading to the development of autoimmune fibrosis and vasculopathy. An important role in the pathogenesis of SSc is played by pathological activation of B-cell immunity, manifested in the disruption of B-cell signaling, B-cell homeostasis, hyperproduction of “profibrotic” cytokines and “pathogenic” autoantibodies. Despite the fact that the pathogenetic mechanisms of SSc associated with dysregulation of B cells and the synthesis of “sclerodermic” autoantibodies have not been sufficiently studied, anti-B-cell therapy is considered one of the important areas of treatment for this disease. The article examines modern concepts about the place of anti-B-cell therapy in the treatment of SSc, primarily in relation to the progression of interstitial lung diseases and skin lesions, and discusses the results of the use of new types of monoclonal antibodies to B-cells and CAR-T-cell therapy.
About the Authors
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Evgeny L. Nasonov.
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
None
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Lidia P. Ananyeva.
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
None
References
1. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724. doi: 10.1038/ni.3731
2. Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420
3. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-315. doi: 10.1038/s41584-019-0211-0
4. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9
5. Beesley CF, Goldman NR, Taher TE, Denton CP, Abraham DJ, Mageed RA, et al. Dysregulated B cell function and disease pathogenesis in systemic sclerosis. Front Immunol. 2023;13:999008. doi: 10.3389/fimmu.2022.999008
6. Melissaropoulos K, Iliopoulos G, Sakkas LI, Daoussis D. Pathogenetic aspects of systemic sclerosis: A view through the prism of B cells. Front Immunol. 2022;13:925741. doi: 10.3389/fimmu.2022.925741
7. Scaletti C, Pratesi S, Bellando Randone S, Di Pietro L, Campochiaro C, Annunziato F, et al. The B-cells paradigm in systemic sclerosis: An update on pathophysiology and B-cell-targeted therapies. Clin Exp Immunol. 2025;219(1):uxae098. doi: 10.1093/cei/uxae098
8. van Oostveen WM, Huizinga TWJ, Fehres CM. Pathogenic role of anti-nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases. Immunol Rev. 2024;328(1):265-282. doi: 10.1111/imr.13390
9. Chepy A, Bourel L, Koether V, Launay D, Dubucquoi S, Sobanski V. Can antinuclear antibodies have a pathogenic role in systemic sclerosis? Front Immunol. 2022;13:930970. doi: 10.3389/fimmu.2022.930970
10. Ananyeva LP, Aleksandrova EN. Autoantibodies in systemic sclerosis: Spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.). doi: 10.14412/1995-4484-2016-86-99
11. Chepy A, Collet A, Launay D, Dubucquoi S, Sobanski V. Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players. J Transl Autoimmun. 2025;10:100272. doi: 10.1016/j.jtauto.2025.100272
12. Rosa I, Romano E, Fioretto BS, Manetti M. Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis. Curr Opin Rheumatol. 2025;37(1):51-63. doi: 10.1097/BOR.0000000000001035
13. Cavazzana I, Vojinovic T, Airo P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic sclerosis-specific antibodies: Novel and classical biomarkers. Clin Rev Allergy Immunol. 2023;64(3):412-430. doi: 10.1007/s12016-022-08946-w
14. Rouvière B, Le Dantec C, Bettacchioli E, Beretta L, Foulquier N, Cao C, et al.; PRECISESADS Clinical Consortium; PRECISESADS Metabolomic Study Group. Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures. Ann Rheum Dis. 2024:ard-2024-225925. doi: 10.1136/ard-2024-225925
15. Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS One. 2019;14(3):e0214202. doi: 10.1371/journal.pone.0214202
16. Kuzumi A, Norimatsu Y, Matsuda KM, Ono C, Okumura T, Kogo E, et al. Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array. Front Immunol. 2023;14:1255540. doi: 10.3389/fimmu.2023.1255540
17. Fukuda E, Tanaka H, Yamaguchi K, Takasaka M, Kawamura Y, Okuda H, et al. Identification and characterization of the antigen recognized by the germ cell mAb TRA98 using a human comprehensive wet protein array. Genes Cells. 2021;26(3):180-189. doi: 10.1111/gtc.12832
18. Matsuda KM, Ebata S, Iwadoh K, Kotani H, Hisamoto T, Kuzumi A, et al. Deciphering autoantibody landscape of systemic sclerosis through systems-based approach: Insights from a B-cell depletion clinical trial. medRxiv. 2024;07.30.24311212. doi: 10.1101/2024.07.30.24311212
19. Akbarzadeh R, Müller A, Humrich JY, Riemekasten G. When natural antibodies become pathogenic: Autoantibodies targeted against G protein-coupled receptors in the pathogenesis of systemic sclerosis. Front Immunol. 2023;14:1213804. doi: 10.3389/fimmu.2023.1213804
20. Zugmaier G, Klinger M, Subklewe M, Zaman F, Locatelli F. B-cell-depleting immune therapies as potential new treatment options for systemic sclerosis. Sclerosis. 2025;3(1):5. doi: 10.3390/sclerosis3010005
21. Nasonov EL (ed.). Anti-B cell therapy in rheumatology: Focus on rituximab. Moscow:IMA-PRESS;2012 (In Russ.).
22. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020-00092-2
23. Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40
24. Robinson WH, Fiorentino D, Chung L, Moreland LW, Deodhar M, Harler MB, et al. Cutting-edge approaches to B-cell depletion in autoimmune diseases. Front Immunol. 2024;15:1454747. doi: 10.3389/fimmu.2024.1454747
25. Mostkowska A, Rousseau G, Raynal NJ. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases. FASEB J. 2024;38(5):e23536. doi: 10.1096/fj.202302259RR
26. Kaegi C, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders. Front Immunol. 2022;12:788830. doi: 10.3389/fimmu.2021.788830
27. Nasonov EL, Rumyantsev AG, Samsonov MYu. Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(3):262-279 (In Russ.). doi: 10.47360/1995-4484-2024-262-279
28. Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. doi: 10.3389/fimmu.2019.01990
29. Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, et al. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: Evidence- and practice-based guidance. Front Immunol. 2023;14:1117699. doi: 10.3389/fimmu.2023.1117699
30. Garzanova LA, Ananyeva LP, Koneva OA, Desinova OV, Starovoytova MN, Ovsyannikova OB, et al. Safety and tolerability of rituximab in the treatment of systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(2):199-206 (In Russ.). doi: 10.47360/1995-4484-2023-199-206
31. Ananyeva LP, Garzanova LA, Koneva OA, Starovoytova MN, Desinova OV, Ovsyannikova OB, et al. Antitopoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):57-63 (In Russ.). doi: 10.47360/1995-4484-2022-57-63
32. Ananyeva LP, Garzanova LA, Desinova OV, Shayakhmetova RU, Starovoitova MN, Koneva OA, et al. The use of “Acellbia” – A biosimilar of rituximab in systemic sclerosis. Dokl Biochem Biophys. 2024;517(1):140-147. doi: 10.1134/S1607672924700844
33. Garzanova LA. Rituximab in the treatment of systemic sclerosis. Literature review. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):466-474 (In Russ.). doi: 10.47360/1995-4484-2023-466-474
34. Macrea M, Ghazipura M, Herman D, Barnes H, Knight SL, Silver RM, et al. Rituximab in patients with systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis. Ann Am Thorac Soc. 2024;21(2):317-327. doi: 10.1513/AnnalsATS.202301-055OC
35. Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, et al. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: A multicenter, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021;204:209-221. doi: 10.1164/rccm.202009-3481OC
36. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489-e497. doi: 10.1016/S2665-9913(21)00107-7
37. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): Open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2022;4(8):e546-e555. doi: 10.1016/S2665-9913(22)00131-X
38. Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, et al. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience. 2021;24(9):103076. doi: 10.1016/j.isci.2021.103076
39. Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, Denton CP, Farrington S, et al. Beyond very early systemic sclerosis: Deciphering pre-scleroderma and its trajectories to open new avenues for preventive medicine. Lancet Rheumatol. 2023;5(11):e683-e694. doi: 10.1016/S2665-9913(23)00212-6
40. Moazedi-Fuerst FC, Kielhauser SM, Hermann J, Meilinger M, Demel U, Stradner MH, et al. Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: A promising surveillance marker of therapy? Scand J Rheumatol. 2015;44(6):519-520. doi: 10.3109/03009742.2015.1069888
41. Bonroy C, Smith V, Deschepper E, De Keyser F, Devreese K. Specific antinuclear antibody level changes after B cell depletion therapy in systemic sclerosis are associated with improvement of skin thickening. J Rheumatol. 2016;43(1):247-249. doi: 10.3899/jrheum.150105
42. Boonstra M, Bakker JA, Grummels A, Ninaber MK, Ajmone Marsan N, Wortel CM, et al. Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis. Arthritis Rheumatol. 2020;72(11):1897-1904. doi: 10.1002/art.41403
43. Simon D, Balogh P, Erdő-Bonyár S, Böröcz K, Minier T, Czirják L, et al. Increased frequency of activated switched memory B cells and its association with the presence of pulmonary fibrosis in diffuse cutaneous systemic sclerosis patients. Front Immunol. 2021;12:686483. doi: 10.3389/fimmu.2021.686483
44. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1):S3. doi: 10.1186/ar3908
45. Fava A, Cimbro R, Wigley FM, Liu QR, Rosen A, Boin F. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther. 2016;18(1):99. doi: 10.1186/s13075-016-0993-2
46. Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563-3571. doi: 10.1002/art.24998
47. Eggleton P, Bremer E, Tarr JM, de Bruyn M, Helfrich W, Kendall A, et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res Ther. 2011;13(6):R208. doi: 10.1186/ar3541
48. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, et al. The anti-CD20 anti-body rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507-1516. doi: 10.1002/art.30314
49. Kuwana M, Medsger TA Jr, Wright TM. Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells. J Immunol. 2000;164(12):6138-6146. doi: 10.4049/jimmunol.164.12.6138
50. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006;169(3):954-966. doi: 10.2353/ajpath.2006.060205
51. Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965
52. She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7(1):52. doi: 10.1038/s41420-021-00437-9
53. Ananyeva LP. Prospects for using tocilizumab in systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(6):632-640 (In Russ.). doi: 10.14412/1995-4484-2015-632-640
54. Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol. 2019;29(2):294-301. doi: 10.1080/14397595.2018.1559909
55. Volkmann E, Tashkin D, Wilhalme H, Lyons M, Kim G, Goldin J, et al. C-reactive protein and interleukin-6: Potential biomarkers of disease activity and treatment response in systemic sclerosis-interstitial lung disease. Ann Rheum Dis. 2022;81:723-724. doi: 10.1136/annrheumdis-2022-eular.1374
56. Kubo S, Satoh-Kanda Y, Todoroki Y, Kanda R, Tanaka H, Ueno M, et al. Effectiveness of rituximab and tocilizumab in managing skin fibrosis in patients with systemic sclerosis. Ann Rheum Dis. 2024;83:180. doi: 10.1136/annrheumdis-2024-eular.1988
57. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0
58. Ghazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM, et al. Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis. Ann Am Thorac Soc. 2024;21(2):328-337. doi: 10.1513/AnnalsATS.202301-056OC
59. Goldman NR, Nihtyanova SI, Beesley CF, Wells AU, Denton CP, Renzoni EA, Mageed R, et al. Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: A real-world cohort analysis. Rheumatology (Oxford). 2025 Jan 3:keaf006. doi: 10.1093/rheumatology/keaf006
60. Boyko OV, Boyko AN, Yakovlev PA, Zinkina-Orikhan AV, Kotov SV, Linkova YuN, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): Pharmacokinetics, pharmacodynamics and safety. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):87-95 (In Russ.). doi: 10.17116/jnevro201911910287
61. Ananyeva LP, Starovoytova MN, Gaydukova IZ, Lukina GV, Zonova EV, Eliseeva LV, et al. The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):158-167 (In Russ.). doi: 10.47360/1995-4484-2025-158-167
62. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165(11):6635-6643. doi: 10.4049/jimmunol.165.11.6635
63. van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901-1912. doi: 10.1056/NEJMoa051568
64. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum. 2004;50(12):4002-4007. doi: 10.1002/art.20674
65. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: Systemic sclerosis as a model system. Curr Dir Autoimmun. 2005;8:55-90. doi: 10.1159/000082087
66. Frampton JE. Inebilizumab: First approval. Drugs. 2020;80(12):1259-1264. doi: 10.1007/s40265-020-01370-4
67. Nie T, Blair HA. Inebilizumab: A review in neuromyelitis optica spectrum disorder. CNS Drugs. 2022;36(10):1133-1141. doi: 10.1007/s40263-022-00949-7
68. Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: A double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 2023;75(12):2185-2194. doi: 10.1002/art.42652
69. Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: A phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131. doi: 10.1186/s13075-016-1021-2
70. Boyles JS, Sadowski D, Potter S, Vukojicic A, Parker J, Chang WY, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023;8(13):e166137. doi: 10.1172/jci.insight.166137
71. Shah K, Leandro M, Cragg M, Kollert F, Schuler F, Klein C, et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clin Exp Immunol. 2024;217(1):15-30. doi: 10.1093/cei/uxae031
72. Perico L, Casiraghi F, Sônego F, Todeschini M, Corna D, Cerullo D, et al. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Front Immunol. 2024;15:1335998. doi: 10.3389/fimmu.2024.1335998
73. Subklewe M, Magno G, Gebhardt C, Bücklein V, Szelinski F, Arévalo HJR, et al. Application of blinatumomab, a bispecific anti-CD3/ CD19 T-cell engager, in treating severe systemic sclerosis: A case study. Eur J Cancer. 2024;204:114071. doi: 10.1016/j.ejca.2024.114071
74. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1
75. Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675. doi: 10.1002/eji.202149675
76. Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24(11):830-845. doi: 10.1038/s41577-024-01035-3
77. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: The history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. doi: 10.3389/fimmu.2023.1188049
78. Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. 2025;84(1):106-114. doi: 10.1136/ard-2024-226142
79. Crickx E, Weill JC, Reynaud CA, Mahévas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: Successes, failures and future perspectives. Kidney Int. 2020;97(5):885-893. doi: 10.1016/j.kint.2019.12.025
80. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917-925. doi: 10.1136/ard.2007.080960
81. Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13(6):1503-1511. doi: 10.1111/ajt.12220
82. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044-3056. doi: 10.1002/art.22810
83. Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(6):1075-1085. doi: 10.1093/rheumatology/key428
84. Robinson JI, Md Yusof MY, Davies V, Wild D, Morgan M, Taylor JC, et al.; MATURA Consortia; MASTERPLANS Consortia. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine. 2022;86:104343. doi: 10.1016/j.ebiom.2022.104343
85. Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: A case series. Lancet Rheumatol. 2025;7(2):e83-e93. doi: 10.1016/S2665-9913(24)00282-0
86. Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, et al. Third-generation CD19 CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024;83(4):543-546. doi: 10.1136/ard-2023-225174
87. Feng J, Hu Y, Chang AH, Huang H. Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: A phase I clinical trial. Blood. 2022;140(Suppl 1):10335-10336. doi: 10.1182/blood-2022-169265
88. Henes J, Pecher AC, Hensen L, Klein R, Stanger A, Faul C, et al. anti-CD19 CAR T cell therapy in systemic sclerosis – experiences from Tuebingen in 3 patients. Ann Rheum Dis. 2024;83:1038. doi: 10.1136/annrheumdis-2024-eular.1746
89. Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al.; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219-227. doi: 10.1136/annrheumdis-2020-217455
90. Cruz T, Jia M, Sembrat J, Tabib T, Agostino N, Bruno TC, et al. Reduced proportion and activity of natural killer cells in the lung of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(5):608-610. doi: 10.1164/rccm.202012-4418LE
91. Padilla CM, Valenzi E, Tabib T, Nazari B, Sembrat J, Rojas M, et al. Increased CD8+ tissue resident memory T cells, regulatory T cells and activated natural killer cells in systemic sclerosis lungs. Rheumatology (Oxford). 2024;63(3):837-845. doi: 10.1093/rheumatology/kead273
92. Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40. doi: 10.1136/ard-2024-226430
93. Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, et al. Treatment of systemic sclerosis-associated interstitial lung disease: Evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2024;209(2):137-152. doi: 10.1164/rccm.202306-1113ST
94. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1201-1213. doi: 10.1002/art.42860
95. Kayser C, Oliveira Delgado SM, Zimmermann AF, Horimoto AMC, Del Rio APT, de Souza Müller C, et al. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis. Adv Rheumatol. 2024;64(1):52. doi: 10.1186/s42358-024-00392-w
96. Denton CP, De Lorenzis E, Roblin E, Goldman N, Alcacer-Pitarch B, Blamont E, et al. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology (Oxford). 2024;63(11):2956-2975. doi: 10.1093/rheumatology/keae394
97. Hassanien M, Elsonbaty A, Hetta H, Moshrif A. Rituximab VE H SUS tocilizumab in patients with systemic sclerosis: 52-week out-comes of a stratified biopsy-driven, open-label, randomized controlled trial. Ann Rheum Dis. 2024;83(Suppl 1):179.1-180. doi: 10.1136/annrheumdis-2024-eular.190
98. Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, et al.; STRAP collaborative group. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): Two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5(11):e648-e659. doi: 10.1016/S2665-9913(23)00241-2
99. Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al.; R4RA collaborative group. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2
100. Avouac J, Cauvet A, Orvain C, Boulch M, Tilotta F, Tu L, et al. Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis. Arthritis Rheumatol. 2024;76(2):268-278. doi: 10.1002/art.42677
101. Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front Immunol. 2021;12:745320. doi: 10.3389/fimmu.2021.745320
102. Hinchcliff M, Khanna D, De Lorenzis E, Di Donato S, Carriero A, Ross RL, et al. Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: A retrospective cohort study. Lancet Rheumatol. 2025 Mar 31:S2665-9913(24)00403-X. doi: 10.1016/S2665-9913(24)00403-X
103. Di Donato S, Ross R, Karanth R, Kakkar V, De Lorenzis E, Bissell LA, et al. Serum type I interferon score for prediction of clinically meaningful disease progression in limited cutaneous systemic sclerosis. Arthritis Rheumatol. 2025 Jan 29. doi: 10.1002/art.43120
104. Wilhelm A, Chambers D, Müller F, Bozec A, Grieshaber-Bouyer R, Winkler T, et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight. 2024;9(12):e179433. doi: 10.1172/jci.insight.179433
Review
For citations:
Nasonov E.L., Ananyeva L.P. Prospects of anti-B-cell therapy for systemic sclerosis. Rheumatology Science and Practice. 2025;63(3):219-228. (In Russ.) https://doi.org/10.47360/1995-4484-2025-219-228
Views:
42
Email this article 